California State Teachers Retirement System Raises Stock Position in Lantheus Holdings, Inc. $LNTH

California State Teachers Retirement System boosted its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 22.3% in the first quarter, HoldingsChannel.com reports. The fund owned 78,207 shares of the medical equipment provider’s stock after purchasing an additional 14,239 shares during the period. California State Teachers Retirement System’s holdings in Lantheus were worth $5,932,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in LNTH. Smartleaf Asset Management LLC grew its position in shares of Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 197 shares during the period. Parallel Advisors LLC raised its position in shares of Lantheus by 122.6% during the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 298 shares during the last quarter. Osterweis Capital Management Inc. purchased a new position in Lantheus in the 2nd quarter valued at about $36,000. Bessemer Group Inc. boosted its holdings in Lantheus by 221.2% in the 1st quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 354 shares during the last quarter. Finally, Los Angeles Capital Management LLC purchased a new stake in Lantheus during the 4th quarter worth approximately $39,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

LNTH has been the topic of a number of research analyst reports. Leerink Partners set a $102.50 price target on Lantheus in a research note on Monday. Truist Financial lowered Lantheus from a “buy” rating to a “hold” rating and decreased their price objective for the company from $125.00 to $102.50 in a report on Monday. Citizens Jmp reaffirmed a “market outperform” rating and set a $115.00 target price on shares of Lantheus in a research note on Monday, June 29th. CJS Securities lowered shares of Lantheus from a “market outperform” rating to a “market perform” rating in a report on Tuesday. Finally, B. Riley Financial reissued a “buy” rating on shares of Lantheus in a research note on Wednesday, July 29th. Five research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $108.11.

Lantheus Stock Up 0.4%

LNTH stock opened at $101.50 on Thursday. The firm has a market cap of $6.61 billion, a PE ratio of 24.46 and a beta of -0.03. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83. The firm’s 50 day moving average price is $104.03 and its 200-day moving average price is $87.63. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $111.86.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The company had revenue of $377.33 million for the quarter, compared to the consensus estimate of $354.48 million. During the same quarter in the previous year, the business earned $1.53 earnings per share. The company’s revenue for the quarter was up 1.2% on a year-over-year basis. On average, equities research analysts anticipate that Lantheus Holdings, Inc. will post 4.5 EPS for the current year.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.